A Study to Evaluate the Safety and Effectiveness of a Digital Therapeutic

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

356

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

June 14, 2024

Study Completion Date

June 14, 2024

Conditions
Suicide, AttemptedSuicidal Ideation
Interventions
DEVICE

OTX-202

Experimental Pscyhoeducation and Intervention App

DEVICE

OTX-000

Other Pscyhoeducation App

BEHAVIORAL

Treatment as Usual

Treatment as usual may include appointments with psychiatrists and other mental health clinicians, suicide risk assessment, supportive listening, crisis resources, clinician assessment, and referral to outpatient treatment.

Trial Locations (6)

11004

Northwell Health, Glen Oaks

43210

Harding Hospital, Columbus

45219

University of Cincinnati, Cincinnati

68131

Common Spirit, Omaha

80204

UCDDenver / Denver Health, Denver

06511

Yale, New Haven

Sponsors
All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Oui Therapeutics, Inc.

INDUSTRY